Genor Biopharma, a Pre-commercial Stage Biopharma Company, Announced the Appointment of Jack Hu as Chief Financial Officer and Chief Strategy Officer

赛前生物制药公司 Genor Biopharma 宣布任命 Jack Hu 为首席财务官兼首席战略官

2019-09-04 02:57:10 BioSpace


SHANGHAI---- Before joining Genor, Dr. Hu served as Managing Director and Head of APAC Healthcare Research at Deutsche Bank, where he covered Asia/China healthcare. Dr. Hu joined Deutsche Bank in 2010 and was ranked No.1 for All-China healthcare research by Institutional Investor magazine from 2015 to 2017. As a seasoned healthcare professional with deep knowledge of the biotech sector, Dr. Hu has nearly 20 years of experience working in equity research, hedge funds and multinational biopharmaceutical companies. Dr. Hu received a Ph.D. in molecular genetics from the M.D. Anderson Cancer Center and began his career at Wyeth . He also covered the US biotech sector as a senior biotech analyst with Oppenheimer. "I believe Dr. Hu’s extensive expertise will help Genor realize its vision of offering innovative, best-in class therapies to serve unmet patient needs. Dr. Hu’s deep knowledge of the healthcare industry and expertise in the financial and capital markets make him a vital addition to Genor’s talented leadership,” said Michael Xu, CEO of Genor, “Dr. Hu joins us at an important inflection point as our business becomes more global. We are excited to work with Dr. Hu in continuing to build strong corporate partnerships and our strategic financial capabilities,” added Mr. Xu. "I am excited to join Genor, a firm that is committed to bringing life changing therapeutics to patients. I look forward to working with this dynamic team to create value for shareholders.” Dr. Hu commented. About Genor Biopharma Genor Biopharma is a clinical-stage biopharmaceutical company located in Zhangjiang, Shanghai, China. Genor is focused on the therapeutic areas of oncology and autoimmune diseases. The Company delivers a portfolio of novel therapies built to address unmet medical needs. The Company’s leading product candidates are late stage innovative monoclonal antibodies. Genor maintains state-of-the-art manufacturing facilities with cGMP capabilities in both Shanghai and Yunnan. View source version on Press: Lily Zhu Source: Genor Biopharma View this news release online at:
上海——在加入 Genor 之前,胡博士曾担任德意志银行 APAC 医疗保健研究的董事总经理和主管,负责亚洲/中国的医疗保健。胡博士于2010年加入德意志银行,2015年至2017年被《机构投资者》( Institutional Investor )杂志评为全中国医疗研究第一。胡博士作为一名经验丰富的医疗保健专业人士,对生物技术领域有着深厚的知识,在股票研究、对冲基金和跨国生物制药公司拥有近20年的工作经验。胡博士从安德森癌症中心获得分子遗传学博士学位,并开始在惠氏(Wyeth)的职业生涯。他还担任奥本海默( Oppenheimer )的高级生物技术分析师,负责美国生物技术行业。 “我相信,胡博士丰富的专业知识将帮助 Genor 实现其提供创新、一流的治疗方案以满足未满足的患者需求的愿景。胡博士对医疗保健行业的深入了解,以及在金融和资本市场的专业知识,使他成为了热那亚杰出领袖的重要补充,”热那亚首席执行官 Michael Xu 说,“随着我们的业务变得更加全球化,胡博士加入了我们的重要转折点。我们很高兴与胡博士合作,继续建立强大的企业合作伙伴关系和我们的战略财务能力,”徐先生补充说。 “我很高兴加入 Genor 公司,这是一家致力于为患者带来改变生命疗法的公司。我期待着与这个充满活力的团队合作,为股东创造价值。”胡博士评论道。 关于 Genor Biopharma Genor Biopharma 是一家位于中国上海张江的临床阶段生物制药公司。Genor 专注于肿瘤和自身免疫性疾病的治疗领域。该公司提供一系列新的治疗方案,以满足未满足的医疗需求。本公司的主导产品候选者为晚期创新型单克隆抗体。Genor 在上海和云南都拥有先进的 cGMP 生产设施。 查看 businesswire 上的源代码。 记者: 朱丽莉 莉莉。Zhu @ 资料来源: Genor Biopharma 在线查看本新闻稿,网址为: